These stocks combine high earnings growth (25–133%), insider confidence, and news-driven momentum across biotech, tech, and renewables. Metsera Inc. (NASDAQ: MTSR): Insider participation in IPO ($54M purchase) and clinical success position MTSR for leadership in metabolic disease treatments. Positive Phase 2a data for MET-097i (ultra-long-acting GLP-1 therapy) released Feb 2025, driving shares 46% YTD gain.

read more